Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Read More…
Industry, Sector and Symbol
Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-1753-217800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£935 million
Profitability
Miscellaneous
Employees915
Next Earnings DateN/A
OptionableNot Optionable
Indivior (LON:INDV) Frequently Asked Questions
What is Indivior's stock symbol?
Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."
What price target have analysts set for INDV?
4 brokers have issued twelve-month price objectives for Indivior's shares. Their predictions range from GBX 114 to GBX 180. On average, they anticipate Indivior's share price to reach GBX 143.50 in the next year. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for Indivior.
What is the consensus analysts' recommendation for Indivior?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Indivior.
Has Indivior been receiving favorable news coverage?
Media coverage about INDV stock has been trending negative on Friday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Indivior earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Indivior.
Who are some of Indivior's key competitors?
Some companies that are related to Indivior include Ironwood Pharmaceuticals (IRWD), Atrion (ATRI), Audentes Therapeutics (BOLD), Polynovo (PNV), Regenxbio (RGNX), Hexo (HEXO), Brookdale Senior Living (BKD), Rhoen Klinikum (RHK), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), Aimmune Therapeutics (AIMT), BioTelemetry (BEAT), Turning Point Therapeutics (TPTX), Health Catalyst (HCAT) and G1 Therapeutics (GTHX).
What other stocks do shareholders of Indivior own?
Who are Indivior's key executives?
Indivior's management team includes the folowing people:
- Mr. Shaun Thaxter, CEO & Exec. Director
- Mr. Mark Crossley, CFO & Exec. Director
- Dr. Christian Heidbreder, Chief Scientific Officer
- Mr. Ingo Elfering, Chief Information & Innovation Officer
- Mr. Jason Thompson, VP of Investor Relations
How do I buy shares of Indivior?
Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Indivior's stock price today?
One share of INDV stock can currently be purchased for approximately GBX 51.66.
How big of a company is Indivior?
What is Indivior's official website?
How can I contact Indivior?
Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.
MarketBeat Community Rating for Indivior (LON INDV)
MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote "Outperform" if you believe INDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days.
